Kelsey Mackenzie Barter
Kelsey Mackenzie Barter has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Soe Soe Mar
Washington University in St. Louis, MO
3 shared publications - Claudia Gambrah-Lyles
Washington University in St. Louis, MO
2 shared publications Anne M. Wagner
From the Department of Neurology, Washington University School of Medicine, St. Louis, MO
1 shared publication- Aye Thant
From the Department of Neurology, Washington University School of Medicine, St. Louis, MO
1 shared publication - Brian Mac Grory
Duke University School of Medicine
1 shared publication - Catherine Fuchs
Division of Child and Adolescent Psychiatry, Department of Psychiatry and Behavioral Sciences Vanderbilt University Medical Center at Village of Vanderbilt Nashville Tennessee USA
1 shared publication
Latest Publications
- 27 October 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (8) , e218575
Pearls & Oy-sters: Diagnosis of Pediatric Tumefactive Multiple Sclerosis With MRI Biomarkers
Multiple sclerosis (MS) is a demyelinating disease of the CNS with an estimated incidence of 0.05–2.85 per 100,000 children. One subtype, tumefactive MS, is particularly rare and difficult to diagn...
- 27 October 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (8) , e218575
Pearls & Oy-sters: Diagnosis of Pediatric Tumefactive Multiple Sclerosis With MRI Biomarkers
Multiple sclerosis (MS) is a demyelinating disease of the CNS with an estimated incidence of 0.05–2.85 per 100,000 children. One subtype, tumefactive MS, is particularly rare and difficult to diagn...
- Open Access
- 25 November 2025
- Published by Elsevier in Pediatric Neurology
- Vol. 175, 174-179
A Scoping Review of Transition to Adult Care in Pediatric-Onset Multiple Sclerosis: An Opportunity to Advance Research
- 25 November 2025
- Published by Elsevier in Pediatric Neurology
- Vol. 175, 174-179
Open AccessA Scoping Review of Transition to Adult Care in Pediatric-Onset Multiple Sclerosis: An Opportunity to Advance Research
- 10 September 2024
- Published by Elsevier in Pediatric Neurology
- Vol. 161, 144-148
The Multiple Sclerosis Prodrome in a Retrospective Pediatric Cohort
- 10 September 2024
- Published by Elsevier in Pediatric Neurology
- Vol. 161, 144-148
The Multiple Sclerosis Prodrome in a Retrospective Pediatric Cohort
- 1 February 2024
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 14 (1) , e200218
Anti-NMDAR Encephalitis Clinical Practice Guideline
A clinical practice guideline (CPG) was created to standardize evaluation and treatment for patients with suspected anti-methyl-d-aspartate receptor (NMDAR) autoimmune encephalitis (AE), the most common AE in children. The objective of this study was to evaluate the CPG effect on time to diagnosis, treatment, and hospital length of stay (LOS). Patients with an inpatient consult to pediatric rheumatology for AE during a 4-year period (period 2) after CPG implementation were identified. Data were extracted and compared with data over the preceding 4-year period (period 1). During period 1, fewer patients underwent diagnostic testing than during period 2 (34 vs 80). Number of patients diagnosed with AE did not differ from period 1 to that from period 2 (NMDAR AE 9 vs 8; seronegative AE 4 vs 5). The average time to diagnostic evaluation with lumbar puncture decreased from 5.4 to 1.5 days (p = 0.0082), and time to treatment decreased from 7.6 to 3.9 days (p = 0.018). LOS showed a trend toward improvement (40.4-29.2 days (p = 0.23)). Creation of a CPG for patients with suspected AE was associated with an improved time to diagnostic evaluation and treatment. With the CPG, more patients underwent AE testing, though total diagnoses remained the same.
- 1 February 2024
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 14 (1) , e200218
Anti-NMDAR Encephalitis Clinical Practice Guideline
A clinical practice guideline (CPG) was created to standardize evaluation and treatment for patients with suspected anti-methyl-d-aspartate receptor (NMDAR) autoimmune encephalitis (AE), the most common AE in children. The objective of this study was to evaluate the CPG effect on time to diagnosis, treatment, and hospital length of stay (LOS). Patients with an inpatient consult to pediatric rheumatology for AE during a 4-year period (period 2) after CPG implementation were identified. Data were extracted and compared with data over the preceding 4-year period (period 1). During period 1, fewer patients underwent diagnostic testing than during period 2 (34 vs 80). Number of patients diagnosed with AE did not differ from period 1 to that from period 2 (NMDAR AE 9 vs 8; seronegative AE 4 vs 5). The average time to diagnostic evaluation with lumbar puncture decreased from 5.4 to 1.5 days (p = 0.0082), and time to treatment decreased from 7.6 to 3.9 days (p = 0.018). LOS showed a trend toward improvement (40.4-29.2 days (p = 0.23)). Creation of a CPG for patients with suspected AE was associated with an improved time to diagnostic evaluation and treatment. With the CPG, more patients underwent AE testing, though total diagnoses remained the same.
- 1 July 2021
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 30 (7) , 105828
Structural and Functional Imaging of the Retina in Central Retinal Artery Occlusion – Current Approaches and Future Directions
- 1 July 2021
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 30 (7) , 105828
Structural and Functional Imaging of the Retina in Central Retinal Artery Occlusion – Current Approaches and Future Directions